drugset / Trial / NCT03902080

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080

Phase 3 Completed 1105 enrolled Urovant Sciences GmbH
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.

Timeline

Start
2019-03-26
Primary completion
2023-06-15
Completion
2023-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Vibegron Unknown 75 mg Oral

Indications